Posted by slinky on September 26, 2003, at 20:17:35
In reply to Re: thanks, didn't know that » Dr. Bob, posted by slinky on September 26, 2003, at 20:05:13
To try to improve the choice available, Glaxo Wellcome investigated with some success a slow-release form of bupropion in bipolar disorder, which has noradrenaline reuptake inhibitory activity but appears to act in depression by blocking dopamine reuptake. So far, it is available in the USA and a licence application is planned for Europe.
poster:slinky
thread:263048
URL: http://www.dr-bob.org/babble/20030923/msgs/263616.html